To market and distribute four products of USpharma Windlas in USA
Granules India announced that its wholly owned subsidiary, Granules Pharmaceuticals Inc. has acquired the exclusive rights from USpharma Windlas, LLC to market and distribute four products in the USA.USpharma Windlas through its subsidiaries (First Time US Generics and Liberty) holds ANDAs for Fingolimod, Prasugrel, Dronedarone and Lurasidone. USpharma Windlas will receive milestone payments and share of the profits from commercial sales.
Granules Pharmaceuticals Inc. will be responsible for the marketing and distribution of the products in the United States, subject to approval of the USFDA.
Powered by Capital Market - Live News
